Verona pharma to present expanded analyses of positive phase 3 enhance studies in copd in multiple presentations at ats 2023

12 abstracts and one symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of pde3 and pde4

VRNA Ratings Summary

VRNA Quant Ranking